CurcuWIN is supported by a strong clinical and safety programme including in vitro, in vivo and multiple human clinical trials
OmniActive’s highly bioavailable curcumin, CurcuWIN, has received self-affirmed GRAS (Generally Recognised as Safe) notification by an expert panel who evaluated the ingredient in accordance with stringent US Food and Drug Administration (FDA) safety criteria.
'OmniActive remains steadfast in delivering innovative, effective and safe ingredients to the marketplace,' said Lynda M. Doyle, Sr VP of Global Marketing, OmniActive.
'CurcuWIN is a truly differentiated ingredient in the increasingly crowded ehanced curcumin market because our robust clinical programme is showing how its higher bioavailability correlates to greater efficacy at a lower dose – what we’ve termed ‘bioavailability with a purpose.’ And now, by gaining GRAS self-affirmation, CurcuWIN sets itself apart yet again.'
In a well-controlled human clinical trial — the first curcumin study of its kind — comparing commercial curcumin products, CurcuWIN increased relative absorption of total curcuminoids 46 times more than standard curcumin.
CurcuWIN was also significantly more bioavailable than other enhanced forms. Moreover, in the recent, groundbreaking FloMeD (Flow Mediated Dilation and Curcumin), CurcuWIN was shown to help support healthy blood flow and circulation at a low dose.
Produced using OmniActive’s proprietary UltraSOL technology, CurcuWIN is a natural turmeric extract with 20% curcuminoids with a similar profile to that found naturally in turmeric.
CurcuWIN is manufactured under cGMP at OmniActive's ISO certified and FDA audited manufacturing facility in Pune, India.